A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

被引:85
作者
Hamberg, A-K [1 ]
Wadelius, M. [1 ]
Lindh, J. D. [2 ]
Dahl, M. L. [2 ]
Padrini, R. [3 ]
Deloukas, P. [4 ]
Rane, A. [2 ]
Jonsson, E. N. [5 ,6 ]
机构
[1] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden
[2] Karolinska Univ, Huddinge Hosp, Div Clin Pharmacol, Stockholm, Sweden
[3] Univ Padua, Dept Clin & Expt Med, Padua, Italy
[4] Wellcome Trust Sanger Inst, Hinxton, England
[5] Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden
[6] Exprimo NV, Mechelen, Belgium
基金
瑞典研究理事会; 英国惠康基金;
关键词
HEALTHY-VOLUNTEERS; PD MODEL; GENOTYPE; THERAPY; ANTICOAGULATION; PHARMACOGENETICS; REQUIREMENTS; PROFILES; IMPACT; TRIAL;
D O I
10.1038/clpt.2010.37
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The objective of the study was to update a previous NONMEM model to describe the relationship between warfarin dose and international normalized ratio (INR) response, to decrease the dependence of the model on pharmacokinetic (PK) data, and to improve the characterization of rare genotype combinations. The effects of age and CYP2C9 genotype on S-warfarin clearance were estimated from high-quality PK data. Thereafter, a temporal dose-response (K-PD) model was developed from information on dose, INR, age, and CYP2C9 and VKORC1 genotype, with drug clearance as a covariate. Two transit compartment chains accounted for the delay between exposure and response. CYP2C9 genotype was identified as the single most important predictor of required dose, causing a difference of up to 4.2-fold in the maintenance dose. VKORC1 accounted for a difference of up to 2.1-fold in dose, and age reduced the dose requirement by similar to 6% per decade. This reformulated K-PD model decreases dependence on PK data and enables robust assessment of INR response and dose predictions, even in individuals with rare genotype combinations.
引用
收藏
页码:727 / 734
页数:8
相关论文
共 30 条
[1]
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].
Anderson, Jeffrey L. ;
Horne, Benjamin D. ;
Stevens, Scott M. ;
Grove, Amanda S. ;
Barton, Stephanie ;
Nicholas, Zachery P. ;
Kahn, Samera F. S. ;
May, Heidi T. ;
Samuelson, Kent M. ;
Muhlestein, Joseph B. ;
Carlquist, John F. .
CIRCULATION, 2007, 116 (22) :2563-2570
[2]
[Anonymous], 2010, Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications
[3]
Beal SS, 1989, NONMEM User's Guides
[4]
Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment [J].
Bertola, JP ;
Mazoyer, E ;
Bergmann, JF ;
Drouet, L ;
Simoneau, G ;
Mahé, I .
THROMBOSIS RESEARCH, 2003, 109 (5-6) :287-291
[5]
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study [J].
Caraco, Y. ;
Blotnick, S. ;
Muszkat, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) :460-470
[6]
D'Angelo A, 2002, HAEMATOLOGICA, V87, P1074
[7]
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs [J].
Friberg, LE ;
Henningsson, A ;
Maas, H ;
Nguyen, L ;
Karlsson, MO .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4713-4721
[8]
Gabrielsson K, 2000, BIOPHARM DRUG DISPOS, V21, P41
[9]
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [J].
Gage, B. F. ;
Eby, C. ;
Johnson, J. A. ;
Deych, E. ;
Rieder, M. J. ;
Ridker, P. M. ;
Milligan, P. E. ;
Grice, G. ;
Lenzini, P. ;
Rettie, A. E. ;
Aquilante, C. L. ;
Grosso, L. ;
Marsh, S. ;
Langaee, T. ;
Farnett, L. E. ;
Voora, D. ;
Veenstra, D. L. ;
Glynn, R. J. ;
Barrett, A. ;
McLeod, H. L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) :326-331
[10]
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy [J].
Hamberg, A-K ;
Dahl, M-L ;
Barban, M. ;
Scordo, M. G. ;
Wadelius, M. ;
Pengo, V. ;
Padrini, R. ;
Jonsson, E. N. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :529-538